• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

紫杉醇两种群体药代动力学模型结构的比较。

Comparison of two types of population pharmacokinetic model structures of paclitaxel.

作者信息

Fransson Martin, Gréen Henrik

机构信息

Programming Environments Laboratory, Department of Computer and Information Science, Linköping University, SE-581 83 Linköping, Sweden.

出版信息

Eur J Pharm Sci. 2008 Feb 5;33(2):128-37. doi: 10.1016/j.ejps.2007.10.005. Epub 2007 Nov 6.

DOI:10.1016/j.ejps.2007.10.005
PMID:18083353
Abstract

Two main types of model structures have been proposed for the pharmacokinetics of paclitaxel; an empirical model structure based on total plasma concentrations of paclitaxel, and a mechanism-based model structure derived from both total and unbound paclitaxel concentrations and concentrations of the formulation vehicle Cremophor EL. The purpose was to compare the two pharmacokinetic model structures when only total paclitaxel concentrations are available. To support the mechanism-based model structure with Cremophor EL concentrations, in silico concentrations were obtained from simulations of a pharmacokinetic model available in the literature. Local algebraic observability was tested on both model structures; the mechanism-based model structure was found, with high probability, not to be algebraically observable if total paclitaxel concentration is considered to be the only model output, and if no kind of prior information is used. Sensitivity analysis was performed to reveal which parameter should be fixed in order to make it locally observable. Parameter estimation was then performed on both model structures using nonlinear mixed effects and data from a clinical study. The estimated mechanism-based model turned out to have a somewhat better fit to data than the corresponding empirical model, delta AIC=-31, where AIC is the Akaike Information Criterion. Hold-out validation was performed on three patients, but did not favour any of the models. In conclusion, since the mechanism-based model structure behaved at least as good as the empirical model structure, it is suggested that the former model structure should be used since it offers a more accurate description of the disposition.

摘要

对于紫杉醇的药代动力学,已经提出了两种主要类型的模型结构;一种是基于紫杉醇总血浆浓度的经验模型结构,另一种是基于紫杉醇总浓度和游离浓度以及制剂载体聚氧乙烯蓖麻油EL浓度的基于机制的模型结构。目的是在仅可获得紫杉醇总浓度时比较这两种药代动力学模型结构。为了用聚氧乙烯蓖麻油EL浓度支持基于机制的模型结构,通过对文献中可用的药代动力学模型进行模拟获得了计算机模拟浓度。对两种模型结构都进行了局部代数可观测性测试;如果将紫杉醇总浓度视为唯一的模型输出且不使用任何类型的先验信息,则发现基于机制的模型结构很可能不是代数可观测的。进行敏感性分析以揭示应固定哪个参数以使其局部可观测。然后使用非线性混合效应和来自一项临床研究的数据对两种模型结构进行参数估计。结果表明,估计的基于机制的模型比相应的经验模型对数据的拟合稍好,AIC差值为-31,其中AIC是赤池信息准则。对三名患者进行了留一法验证,但没有支持任何一个模型。总之,由于基于机制的模型结构表现至少与经验模型结构一样好,因此建议使用前一种模型结构,因为它能更准确地描述药物处置情况。

相似文献

1
Comparison of two types of population pharmacokinetic model structures of paclitaxel.紫杉醇两种群体药代动力学模型结构的比较。
Eur J Pharm Sci. 2008 Feb 5;33(2):128-37. doi: 10.1016/j.ejps.2007.10.005. Epub 2007 Nov 6.
2
A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling.使用非线性混合效应模型对聚氧乙烯蓖麻油(Cremophor EL)的药代动力学进行群体分析。
Cancer Chemother Pharmacol. 2002 Jul;50(1):16-24. doi: 10.1007/s00280-002-0459-x. Epub 2002 May 1.
3
Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients.新型纳米滴制剂与泰素相比,癌症患者中紫杉醇总含量及游离紫杉醇的机制性群体药代动力学研究
Cancer Chemother Pharmacol. 2009 May;63(6):1049-63. doi: 10.1007/s00280-008-0827-2. Epub 2008 Sep 13.
4
Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients.用于中性粒细胞减少症的多池细胞寿命模型,以评估癌症患者中两种制剂的游离紫杉醇的群体药效学。
Cancer Chemother Pharmacol. 2009 May;63(6):1035-48. doi: 10.1007/s00280-008-0828-1. Epub 2008 Sep 13.
5
Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients.聚氧乙烯蓖麻油在患者体内会导致紫杉醇呈现(伪)非线性药代动力学。
Br J Cancer. 1999 Sep;81(2):330-5. doi: 10.1038/sj.bjc.6690696.
6
Disposition of [G-(3)H]paclitaxel and cremophor EL in a patient with severely impaired renal function.[G-(3)H]紫杉醇和聚氧乙烯蓖麻油在一名严重肾功能受损患者体内的处置情况。
Drug Metab Dispos. 1999 Nov;27(11):1300-5.
7
Mechanism-based pharmacokinetic model for paclitaxel.基于机制的紫杉醇药代动力学模型。
J Clin Oncol. 2001 Oct 15;19(20):4065-73. doi: 10.1200/JCO.2001.19.20.4065.
8
Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications.聚氧乙烯蓖麻油介导的紫杉醇在人体血液中分布的改变:临床药代动力学意义
Cancer Res. 1999 Apr 1;59(7):1454-7.
9
The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients.助溶剂聚氧乙烯蓖麻油(Cremophor EL)会限制癌症患者口服紫杉醇的吸收。
Br J Cancer. 2001 Nov 16;85(10):1472-7. doi: 10.1054/bjoc.2001.2118.
10
Measurement of fraction unbound paclitaxel in human plasma.人血浆中游离紫杉醇分数的测定。
Drug Metab Dispos. 2000 Oct;28(10):1141-5.

引用本文的文献

1
Drug delivery process simulation-Quantifying the conformation dynamics of paclitaxel and cremophor EL.药物递送过程模拟——量化紫杉醇和聚氧乙烯蓖麻油的构象动力学
PLoS One. 2025 May 12;20(5):e0313813. doi: 10.1371/journal.pone.0313813. eCollection 2025.
2
Gravito-inertial ambiguity resolved through head stabilization.通过头部稳定解决重力惯性模糊问题。
Proc Math Phys Eng Sci. 2019 Mar;475(2223):20180010. doi: 10.1098/rspa.2018.0010. Epub 2019 Mar 27.
3
Model-based meta-analysis for quantifying Paclitaxel dose response in cancer patients.
基于模型的荟萃分析用于量化癌症患者紫杉醇的剂量反应。
CPT Pharmacometrics Syst Pharmacol. 2014 May 21;3(5):e115. doi: 10.1038/psp.2014.14.